Clear, unbiased guides on GLP-1
medications, semaglutide, and metabolic treatments
for non-diabetics.
GLP-1 receptor agonists started with diabetes. Then obesity. Then cardiovascular protection. Now researchers are asking whether microdosing GLP-1 for autoimmune conditions — IBD, rheumatoid arthritis, multiple sclerosis, Hashimoto’s — could be the next chapter. A physician breaks down the mechanism, the evidence, and what’s still ahead of the science.
Is phentermine a GLP-1? No — but both suppress appetite. Here’s what actually separates them mechanistically, and which may be right for you.
There’s a conversation that happens in clinics every day. A patient walks out with a new diagnosis — obstructive sleep apnea — and a physician who means well delivers one of two sentences. The first: Lose weight. Which is both medically accurate and spectacularly unhelpful as a standalone prescription. The patient nods, already knowing, already…
GLP-1 long-term side effects are one of the most searched questions once patients reach month four or five of treatment. Around that point, something shifts. The nausea has mostly faded. The appetite is different in a way that’s become familiar. The scale is moving. And then, quietly, a different question moves in — one that…
GLP-1 constipation is common, predictable, and manageable — if you know the full protocol. Most advice stops at water and fiber. Here’s what comes next, in order.
GLP-1 medications can cost over $1,000/month at sticker price —
but most patients pay far less. A complete guide to every
access route, from savings cards to telehealth to compounding.
Semaglutide vs tirzepatide — the data is clear about what these drugs do in populations. What it can’t tell you is which one is right for you. A clinical breakdown of the evidence, the mechanism differences, and a framework to make that decision with your doctor.
GLP-1 starts working within hours. Your results depend on what happens over the next 16 weeks. Here’s the real timeline — week by week — and what actually determines whether this medication works for you.
GLP-1. Non diabetic. If these two words feel like they
don’t belong in the same sentence — that reaction is
exactly why you’re here. For years, they didn’t.
This guide is the clinical answer non diabetic adults
deserve: how GLP-1 receptor agonists work, who is
actually a candidate, what three independent
meta-analyses say about weight and cardiometabolic
outcomes, and how to access these medications without
being sold something first.
Written by a physician with 25 years of clinical
experience. No hype. No moral lecture. Just evidence.